Implementation of a process-scale adenovirus purification with a single-use platform
June 17-22, 2018
Adenovirus vectors are finding increasing application within the vaccine and gene therapy industries. Companies developing adenovirus-based biopharmaceuticals will benefit from single-use process platforms that are quick and easy to install and have been demonstrated previously to produce purified adenovirus. The platform can be adapted to new adenovirus products with a minimum investment of time and resource in process development activities. We have assembled a platform from existing and proven technologies, available from lab to production scale, that meet the quality requirements of the vaccine industry. The platforms includes clarification, ultrafiltration/diafiltration, chromatography and sterile filtration steps. The approach has been successfully demonstrated for the purification of an Adenovirus serotype 5 vector, at the 20 L scale. It allows the complete purification of the vaccine in one day.
Amélie Boulais, Miyako Hirai, Maria Mellado, and Cristina Peixoto, "Implementation of a process-scale adenovirus purification with a single-use platform" in "Vaccine Technology VII", Amine Kamen, McGill University Tarit Mukhopadhyay, University College London Nathalie Garcon, Bioaster Charles Lutsch, Sanofi Pasteur Eds, ECI Symposium Series, (2018). https://dc.engconfintl.org/vt_vii/77